U.S. Markets closed

Why this pain-killing opioid is spinning into a new company

Ron Leuty
Why this pain-killing opioid is spinning into a new company

Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.